Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients
Joshua J. Gruber, A. Dimitrios Colevas
The Oncologist (2015) Vol. 20, Iss. 2, pp. 113-126
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Robert I. Haddad, Lindsay A. Bischoff, Douglas W. Ball, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 8, pp. 925-951
Open Access | Times Cited: 332
Molecular targets of tyrosine kinase inhibitors in thyroid cancer
Poupak Fallahi, Silvia Martina Ferrari, Maria Rosaria Galdiero, et al.
Seminars in Cancer Biology (2020) Vol. 79, pp. 180-196
Closed Access | Times Cited: 113
Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
Maria E. Cabanillas, Shunji Takahashi
Seminars in Oncology (2018) Vol. 46, Iss. 1, pp. 57-64
Open Access | Times Cited: 108
Tumor-Associated Mast Cells in Thyroid Cancer
Carla Visciano, Nella Prevete, Federica Liotti, et al.
International Journal of Endocrinology (2015) Vol. 2015, pp. 1-8
Open Access | Times Cited: 66
Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer
Aditi Sharma, Lalit Sharma, Shouvik Kumar Nandy, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 750-750
Open Access | Times Cited: 18
Molecular Targeted Therapies of Aggressive Thyroid Cancer
Silvia Martina Ferrari, Poupak Fallahi, Ugo Politti, et al.
Frontiers in Endocrinology (2015) Vol. 6
Open Access | Times Cited: 60
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop
Veronica Vella, Maria Luisa Nicolosi, P Cantafio, et al.
Endocrine Related Cancer (2018) Vol. 26, Iss. 1, pp. 197-214
Open Access | Times Cited: 46
Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
Naomi Kiyota, Bruce Robinson, Manisha H. Shah, et al.
Thyroid (2017) Vol. 27, Iss. 9, pp. 1135-1141
Open Access | Times Cited: 42
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Nigel Fleeman, Rachel Houten, Marty Chaplin, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 41
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Nigel Fleeman, Rachel Houten, A Bagust, et al.
Health Technology Assessment (2020) Vol. 24, Iss. 2, pp. 1-180
Open Access | Times Cited: 36
Clinical outcomes of radioactive 125 I seed brachytherapy for recurrent refractory differentiated thyroid cancers
Zhen Gao, Yixing Li, Jinzhao Dai, et al.
Research Square (Research Square) (2025)
Closed Access
Resolution of the Expert Council on the problems of diagnosis and therapy of RET-positive thyroid cancer
Article Editorial
Head and neck tumors (HNT) (2025) Vol. 15, Iss. 1, pp. 89-94
Open Access
Lenvatinib: A Review in Refractory Thyroid Cancer
James E. Frampton
Targeted Oncology (2016) Vol. 11, Iss. 1, pp. 115-122
Closed Access | Times Cited: 36
Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-κB signaling pathway
Xian Cheng, Xin Yao, Shichen Xu, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 103, pp. 490-498
Closed Access | Times Cited: 35
Therapeutic options for advanced thyroid cancer
Apoorva Jayarangaiah, Gurinder Sidhu, Jean Brown, et al.
International Journal of Clinical Endocrinology and Metabolism (2019) Vol. 5, Iss. 1, pp. 026-034
Open Access | Times Cited: 35
Cabozantinib in Thyroid Cancer
Poupak Fallahi, Silvia Martina Ferrari, Flavia Di Bari, et al.
Recent Patents on Anti-Cancer Drug Discovery (2015) Vol. 10, Iss. 3, pp. 259-269
Open Access | Times Cited: 35
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Jaume Capdevila, José Trigo, Javier Aller, et al.
European Journal of Endocrinology (2017) Vol. 177, Iss. 4, pp. 309-317
Open Access | Times Cited: 34
CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma
Thomas Werner, Christina Förster, Levent Dizdar, et al.
Journal of Cancer (2018) Vol. 9, Iss. 6, pp. 929-940
Open Access | Times Cited: 32
Selective use of vandetanib in the treatment of thyroid cancer
Alessandro Antonelli, Poupak Fallahi, Flavia Di Bari, et al.
Drug Design Development and Therapy (2015), pp. 3459-3459
Open Access | Times Cited: 31
Targeted therapies in thyroid cancer: an extensive review of the literature
Athanasios Bikas, Shivangi Vachhani, Kirk Jensen, et al.
Expert Review of Clinical Pharmacology (2016) Vol. 9, Iss. 10, pp. 1299-1313
Closed Access | Times Cited: 31
Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition
Esther Ekpe-Adewuyi, Ana Lopez-Campistrous, Xiaoyun Tang, et al.
Oncotarget (2016) Vol. 7, Iss. 50, pp. 83684-83700
Open Access | Times Cited: 31
<p>Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis</p>
Shitong Yu, Jun-Na Ge, Jingyi Luo, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 1525-1532
Open Access | Times Cited: 28
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5731-5731
Open Access | Times Cited: 15
The Chinese herb Prunella vulgaris promotes apoptosis in human well-differentiated thyroid carcinoma cells via the B-cell lymphoma-2/Bcl-2-associated X protein/caspase-3 signaling pathway
Detao Yin, Mengyuan Lei, Jianhui Xu, et al.
Oncology Letters (2017) Vol. 14, Iss. 2, pp. 1309-1314
Open Access | Times Cited: 27
Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer
Sujata Narayanan, A. Dimitrios Colevas
Current Treatment Options in Oncology (2016) Vol. 17, Iss. 6
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top